Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Cathepsin Y" patented technology

Cathepsin cysteine protease inhibitors

ActiveUS20050240023A1Treating and preventing cathepsin dependent conditionBiocideOrganic chemistryCathepsin KCathepsin
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Owner:AXYX PHARMA INC +1

Cyanoalkylamino derivatives as protease inhibitors

The present invention is directed to novel cyanoalkylamino derivatives that are inhibitors of cysteine protease such as cathepsins K, S, B and L, in particular cathepsin K Pharmaceutical composition comprising these compounds, method of treating diseases mediated by unregulated cysteine protease activity, in particular cathepsin K utilizing these compounds and methods of preparing these compounds are also disclosed.
Owner:AXYX PHARMA INC +1

Peptidic compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:QUEST DIAGNOSTICS INVESTMENTS LLC

Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture

Method of diagnosing persistent, chronic synovitis and progressive joint degradation in the joint of a mammal. The method including providing a test sample comprising synovial fluid, cell or tissue from the joint of a mammal; detecting the presence of bacterial DNA, measuring the concentration of one or more biomarkers being cathepsin K, MMP-2 and -9, cathepsin S, tartrate-resistant acid phosphatase, invariant chain, CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD44+ mononuclear cells, Toll-like receptor-2, Toll-like receptor-9, or a combination thereof; and, comparing the concentration of the biomarker from the test sample to a corresponding biomarker concentration in a control sample from healthy dogs, or an internal PBMC control sample, wherein a statistically significant elevated concentration of the biomarker in the test sample indicates that the mammal's joint is diseased.
Owner:WISCONSIN ALUMNI RES FOUND

4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis

InactiveUS20060166966A1Treating and preventing cathepsin dependent conditionBiocideOrganic chemistryCathepsin KCathepsin Y
This invention relates to compounds of formula (I) which are cysteine protease inhibitors, in particular, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Owner:MERCK FROSST CANADA INC

Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R1, R2, R3, R4, R5, R6, R8, R9 and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
Owner:BOEHRINGER INGELHEIM PHARMA INC

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (Ia) and (Ib) where R2, R3, R4, R6, R8 and Y are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds
Owner:BOEHRINGER INGELHEIM PHARMA INC

Making method of preconditioned shelled Penaeus vannamei Boone

The invention discloses a making method of preconditioned shelled Penaeus vannamei Boone. The method comprises the following steps: removing heads, shells and digestive tracts from fresh Penaeus vannamei Boone, and washing and draining the Penaeus vannamei, or unfreezing frozen shelled Penaeus vannamei Boone at room temperature to obtain unfrozen shelled Penaeus vannamei Boone for later use; preparing a preconditioning preserving liquid; uniformly mixing the shelled Penaeus vannamei Boone with the preserving liquid; placing the obtained shelled Penaeus vannamei Boone and preserving liquid mixture in a vacuum rolling machine, and rolling the mixture; taking out the rolled shelled Penaeus vannamei Boone, and carrying out vacuum packaging; and carrying out freezing storage or refrigeration on the packaged shelled Penaeus vannamei Boone. Food grade components contained in the preconditioning preserving liquid can effectively inhibit tissue protease and microorganisms of the shelled Penaeus vannamei Boone in the processing process and prevent proteolysis and microbial propagation induced quality reduction, and the rolling preserving increases the muscle elasticity of the shelled Penaeus vannamei Boone and increases the preserving efficiency.
Owner:JIANGSU ACADEMY OF AGRICULTURAL SCIENCES

Alpha ketoamide compounds as cysteine protease inhibitors

The present invention relates to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:探索诊断投资有限责任公司

Cysteine protease inhibitors

of the formula (IV): where: R1=R'C(O), R'SO2, R'=a bicyclic, saturated or unsaturated, 8-12 membered ring system containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or R'=a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least one substituent selected from group a) and / or c) and which may optionally bear one or two further substituents selected from group b); R4=H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl; R3=C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl, Ar; R5=C1-7-alkyl, halogen, Ar-C1-7-alkyl, C1-3-alkyl-CONR3R4 or a bulky amine R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R<ix>, C1-3-alkyl-C(O)-NHR<ix >or CH2XAr q is 0 or 1 have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.
Owner:MEDIVIR AB

Novel compounds and compositions as cathepsin inhibitors

Novel inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
Owner:AVENTIS PHARMA INC

Method for tenderizing sea cucumbers based on biological enzymes

The present invention relates to a method for tenderizing sea cucumbers based on biological enzymes. The method comprises the following steps: sea cucumber body wall tissue blocks are soaked in a biological enzyme solution; the biological enzymes are selected from one or more of collagenase, cathepsin and pepsin; the enzyme activity concentration of the biological enzyme solution is 200-800 U / mL;the enzyme dosage per gram of the sea cucumber body wall tissue blocks is 200-800 U; the temperature of the biological enzyme solution is 20-60 DEG C; and the soaking time is 10-120 min. The providedmethod effectively decomposes collagen and structural proteins, and reduces the hardness of the sea cucumber tissues.
Owner:DALIAN POLYTECHNIC UNIVERSITY

Cathepsin inhibitor, preparation method and applications thereof

The invention relates to the field of medicinal chemistry, particularly to a cathepsin inhibitor, a preparation method and applications thereof, more particularly to a tumor-associated cathepsin L inhibitor and a tumor-associated cathepsin D inhibitor, and a preparation method of the tumor-associated cathepsin L inhibitor and the tumor-associated cathepsin D inhibitor. Specifically the present invention further relates to a novel peptoid compound or a pharmaceutically acceptable salt thereof, a solvate, a pharmaceutical composition and a pharmaceutical preparation, a preparation method of thecompound, and applications of the peptoid compound or the pharmaceutically acceptable salt thereof, the solvate, the pharmaceutical composition and the pharmaceutical preparation in preparation of antitumor drugs, wherein the structure formula of the compound is defined in the specification, and R1, R2 are defined in the claims and the specification. The formula (I) is defined in the specification.
Owner:SHENYANG PHARMA UNIVERSITY

Method for cultivating selenium-enriched Cordyceps militaris

The invention belongs to the technical field of cultivation of Cordyceps militaris, in particular to a method for cultivating selenium-enriched Cordyceps militaris. According to the method for cultivating the selenium-enriched Cordyceps militaris, a strain activation culture medium, a seed liquid culture medium and a liquid fermentation medium are carefully screened, molasses, sucrose, peptone, radix astragali, yeast selenium, radish, Enteromorpha residue, egg white, potassium dihydrogen phosphate and magnesium sulfate are taken as main nutrient raw materials, and cathepsin and cellulase are added, so that dissolution and absorption of various raw materials are facilitated; and added EDTA-4Na also contributes to transfer and absorption of selenium. Furthermore, in the method of the presentinvention, the content of selenium in mycelia of Cordyceps militaris is further increased by adding amino acid chelated calcium to the fermentation medium to better induce absorption and accumulationof selenium.
Owner:安徽祥康生物工程有限公司

Silinane compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.
Owner:SCHERING AG

Nitriles useful as reversible inhibitors of cysteine proteases

Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Amidino compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:SCHERING AG

Cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:CELERA CORPORATION

Cathespin cysteine protease inhibitors

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
Owner:MERCK CANADA

Haloalkyl Containing Compounds as Cysteine Protease Inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC

Di-fluoro containing compounds as cysteine protease inhibitors

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Owner:VIROBAY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products